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Background
Type I interferons (IFNs) stimulate the establishment of
an antiviral state in infected and susceptible cells and play
a key role in the initial containment of many virus infec-
tions. Most viruses have evolved at least one strategy for
the evasion of this antiviral response. The acute burst of
viral replication in primary HIV-1 infection is associated
with a transient elevation in systemic IFN-alpha levels.
This study addressed the relationship between acute-
phase viral sensitivity to type I IFNs in vitro and the prog-
nostically-important setpoint persisting viral load estab-
lished in subjects with primary HIV-1 infection.
Methods
Primary HIV-1 isolates were derived from a cohort of
acutely-infected patients who subsequently went on to
establish setpoint persisting viral loads of between 3,000
and 900,000 viral RNA copies/ml. An in vitro system using
stimulated peripheral blood mononuclear cells was
devised to assess the sensitivity of these virus isolates to
the antiviral effects of type I IFNs.
Results
Both IFN-alpha and IFN-beta were shown to inhibit the
replication of the lab-adapted HIV-1 isolate W6BC in vitro.
IFN-beta was found to require a significantly shorter expo-
sure time than IFN-alpha for exertion of its full antiviral
effect. In vitro IFN-alpha and IFN-beta IC50 values were
successfully calculated for an initial set of acute-phase pri-
mary HIV-1 isolates. The IFN sensitivity of different HIV-
1 isolates was shown to vary, and preliminary results sug-
gested a correlation between IFN sensitivity and setpoint
viral load. A more extensive group of virus isolates are cur-
rently being studied to confirm or deny this hypothesis.
Conclusion
Primary HIV-1 isolates differ in sensitivity to control by
type 1 IFNs. Preliminary results suggest that viral IFN sen-
sitivity could be among the factors that impact on the set-
point persisting viral load established in vivo.
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